Skip to main content
Agfa-Gevaert NV logo

Agfa-Gevaert NV — Investor Relations & Filings

Ticker · AGFB ISIN · BE0003755692 LEI · 549300IHBDUTUNQJJB79 BR Manufacturing
Filings indexed 771 across all filing types
Latest filing 2023-05-09 Interim / Quarterly Rep…
Country BE Belgium
Listing BR AGFB

About Agfa-Gevaert NV

https://www.agfa.com/corporate/

Agfa-Gevaert NV is a multinational corporation that develops, manufactures, and distributes a range of analog and digital imaging systems and IT solutions. The company's activities are concentrated in several divisions. The HealthCare IT division provides integrated solutions for medical imaging and information management, including its Enterprise Imaging platform which utilizes artificial intelligence. The Digital Print & Chemicals division supplies the graphics industry with products such as large-format inkjet printers, inks, software, and synthetic papers. The Specialty Products division develops advanced materials, including high-performance films and membranes for various industrial applications, such as the production of green hydrogen. The company leverages its extensive experience in imaging technology to deliver innovative solutions to professional and industrial markets.

Recent filings

Filing Released Lang Actions
CO_20230509_Q1_UK statements.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed, unaudited consolidated financial statements, including the Statement of Profit or Loss, Statement of Comprehensive Income, and Statement of Financial Position for the quarter ending March 31, 2023. It provides comparative data for Q1 2022 and year-end 2022. Since it contains substantive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2023
2023-05-09 English
CO_20230509_Q1_NL statements.pdf
Interim / Quarterly Report Classification · 100% confidence The document contains detailed, unaudited consolidated financial statements (Income Statement, Statement of Comprehensive Income, and Balance Sheet) for the first quarter (Q1 2023) compared to Q1 2022. It provides substantive financial data rather than just highlights or an announcement. This fits the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-09 Dutch
CO_20230509_Q1_UK final.pdf
Earnings Release Classification · 100% confidence The document provides a detailed commentary and financial breakdown for the Agfa-Gevaert Group's performance in the first quarter of 2023 (Q1 2023). It includes key performance indicators (Revenue, Adjusted EBITDA, Net loss), segment-specific results (HealthCare IT, Radiology Solutions, Digital Print & Chemicals), and an outlook. The structure, content (quarterly figures, segment analysis, management commentary), and explicit mention of 'Q1 2023' strongly indicate this is a comprehensive report covering a period shorter than a full year. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not an Earnings Release (ER) because it contains extensive detail and tables, not just highlights. It is also not a 10-K (Annual Report) as it covers only one quarter. Q1 2023
2023-05-09 English
CO_20230509_Q1_NL final.pdf
Earnings Release Classification · 100% confidence The document is a detailed financial report covering the results for the 'eerste kwartaal van 2023' (first quarter of 2023). It includes key performance indicators (KPIs) like revenue, Adjusted EBITDA, Net Loss, segment breakdowns (HealthCare IT, Radiology Solutions, Digital Print & Chemicals), management commentary from the CEO, and outlook statements. The structure, content (financial tables, segment analysis, outlook), and explicit mention of quarterly results strongly indicate this is a comprehensive interim financial report, not just a brief announcement. This aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is too detailed to be an Earnings Release (ER) and is clearly a full report for a period shorter than a year. Q1 2023
2023-05-09 Dutch
proxy-AGM-final.pdf
Proxy Solicitation & Information Statement Classification · 98% confidence The document is explicitly titled '# PROXY' and details the appointment of a representative to vote at the 'Annual Meeting of Shareholders' scheduled for May 9, 2023. The agenda items include the acknowledgement of the Annual Report, approval of accounts, approval of the Remuneration Report, discharge of directors, and changes in the Board of Directors. This material is directly related to soliciting shareholder votes and providing necessary information for the Annual General Meeting (AGM). This aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI), which covers materials sent to shareholders to request votes for meetings. While it relates to the AGM, PSI is more specific for the proxy form itself than AGM-R (which is for presentations/materials shared *during* the meeting).
2023-04-07 English
AV-volmacht-final.pdf
AGM Information Classification · 99% confidence The document text is a formal proxy form ('V O L M A C H T' which translates to Power of Attorney/Proxy) for shareholders to appoint a representative for a meeting. The text explicitly mentions the 'Jaarvergadering' (Annual General Meeting) scheduled for May 9, 2023, and lists the agenda items, which include the review and approval of the Annual Report and Financial Statements for the year ended December 31, 2022, as well as the approval of the Remuneration Report and the reappointment of directors. Since this document is the material used to solicit shareholder votes and provide information ahead of the Annual General Meeting, it aligns perfectly with the definition of Proxy Solicitation & Information Statement (PSI). It is not the AGM presentation itself (AGM-R), nor the Annual Report (10-K), but the document used to manage voting rights for that meeting.
2023-04-07 Dutch

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.